Article
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Nature communications - 7 Jun 2021
Hasni Sarfaraz A, Gupta Sarthak, Davis Michael, Poncio Elaine, Temesgen-Oyelakin Yenealem, Carlucci Philip M, Wang Xinghao, Naqi Mohammad, Playford Martin P, Goel Rishi R, Li Xiaobai, Biehl Ann J, Ochoa-Navas Isabel, Manna Zerai, Shi Yinghui, Thomas Donald, Chen Jinguo, Biancotto Angélique, Apps Richard, Cheung Foo, Kotliarov Yuri, Babyak Ashley L, Zhou Huizhi, Shi Rongye, Stagliano Katie, Tsai Wanxia Li, Vian Laura, Gazaniga Nathalia, Giudice Valentina, Lu Shajia, Brooks Stephen R, MacKay Meggan, Gregersen Peter, Mehta Nehal N, Remaley Alan T, Diamond Betty, O'Shea John J, Gadina Massimo, Kaplan Mariana J
Abstract excerpt
Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In lupus animal models, the Janus kinase (JAK) inhibitor tofacitinib improves clinical features, immune dysregulation and vascular dysfunction. We conducted a randomized, double-blind, placebo-controlled...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.